NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint BluePrint Breast Cancer Kit Co-Validation Study
Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit IRVINE, CA, AMSTERDAM, and PARIS โ 5 December 2017 โ Read More
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint and BluePrint Across Breast Cancer Patient Populations
IRVINE, CA, AMSTERDAM, NETHERLANDS โ 30 November 2017 โ Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Read More
Agendiaโs MammaPrint Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
CMS established the 2018 payment rate for MammaPrintโs new CPT code 81521 thus securing continued access to MammaPrint for Medicare/Medicaid beneficiaries The new determination and increased allowance follows an impressive Q3 which saw MammaPrintโs U.S. Read More
